Lidocaine Pregnancy and Breastfeeding Warnings
Lidocaine is also known as: Anestacaine, DentiPatch, Dilocaine, L-Caine, Lidoject 1, Lidoject 2, Nervocaine, Truxacaine, UAD Caine, Xylocaine Dental Cartridges, Xylocaine Duo-Trach Kit, Xylocaine HCl, Xylocaine HCl For Spinal, Xylocaine-MPF
Lidocaine Pregnancy Warnings
Lidocaine has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancies. Use in labor and delivery may result in fetal and neonatal toxicity. Lidocaine should only be given during pregnancy and in labor and delivery when need has been clearly established.
Lidocaine rapidly crosses the human placenta. Data have revealed that the average umbilical cord to plasma concentration ratio ranges from 0.5 to 0.7. The free fraction of lidocaine in neonates may be higher than in the mother due to decreased plasma protein binding. Decreased Apgar scores, apnea, fixed and dilated pupils, hypotonia, and seizures have been reported in some neonates whose serum levels were 2.5 mg/L or more. Some data have shown that neonates whose mothers received continuous lidocaine epidural anesthetic blocks had decreased muscle tone relative to neonates whose mothers received placebo. Other data have not supported this association. The placental transfer of lidocaine after prolonged continuous maternal IV administration has been described. After 14.1 g of lidocaine (50 mg/hr for 282 hours), the umbilical vein/maternal vein lidocaine concentration ratio averaged 0.52 (average maternal and umbilical vein concentrations of 1.6 and 0.83 mcg/mL, respectively). These data are similar to those described after shorter periods of administration of lidocaine during labor. The Collaborative Perinatal Project monitored 50,282 mother-child pairs, of whom 293 received lidocaine as a local anesthetic agent during lunar months one through four. Of the 293 pairs, 16 children with any malformation were born. Statistically, the overall standardized relative risk (SRR) of malformations was 0.85, indicating no association of this drug with broad classes of malformations. The only SRR greater than 1.5 was for the respiratory tract (2.02, based on three malformed children) and tumors (1.89, based on two malformed children). The statistical significance of these values are unknown. Data from the Michigan Medicaid Birth Defects Study has failed to reveal an association between the use of lidocaine and congenital abnormalities (written communication, Franz Rosa, MD, Food and Drug Administration, 1994). This was a retrospective study of 229,101 completed pregnancies between 1985 and 1992, of which 165 were exposed to lidocaine at some time during the first trimester, and 525 were exposed to the drug at any time during pregnancy. There were 7 total and 3 cardiovascular defects observed (6 and 3 were expected, respectively). There were two instances of polydactyly. There were no observations of cleft palate, spina bifida, limb reduction, or hypospadias. None of the observations achieved statistical significance. These data do not support an association between lidocaine and birth defects.
Lidocaine Breastfeeding Warnings
Limited data have shown that the average milk lidocaine levels were approximately 40% of maternal serum levels. In one case, a 37-year-old woman who had received two lidocaine boluses of 75 and 50 mg, then a continuous infusion of 2 mg per minute, had lidocaine levels of 2.0 and 0.8 mg/L in her serum and milk, respectively (milk to plasma concentration ratio of 0.4). The milk sample was obtained two hours after the lidocaine infusion was stopped. In another case, lidocaine and its metabolite, MEGX, were found in breast milk after injection of lidocaine 20 mg for a dental procedure. The milk to plasma lidocaine and MEGX concentration ratios in this case were 1.1 and 1.8, respectively.
Lidocaine is excreted into human milk. Side effects in the nursing infant are unlikely and would probably be limited to an idiosyncratic or allergic reaction. The manufacturer recommends caution when administering lidocaine to nursing women.
References for pregnancy information
- Scanlon JW, Brown WU Jr, Weiss JB, Alper MH "Neurobehavioral responses of newborn infants after maternal epidural anesthesia." Anesthesiology 40 (1974): 121-8
- Rotmensch HH, Elkayam U, Frishman W "Antiarrhythmic drug therapy during pregnancy." Ann Intern Med 98 (1983): 487-97
- Lin SK "The effect of pregnancy on the plasma protein binding of lidocaine: does it matter?" Anesth Analg 80 (1995): 1063
- "Product Information. Xylocaine (lidocaine)." Astra USA, Westborough, MA.
- Alakokko TI, Pienimaki P, Herva R, Hollmen AI, Pelkonen O, Vahakangas K "Transfer of lidocaine and bupivacaine across the isolated perfused human placenta." Pharmacol Toxicol 77 (1995): 142-8
- Banzai M, Sato S, Tezuka N, Komiya H, Chimura T, Hiroi M "Placental transfer of lidocaine hydrochloride after prolonged continuous maternal intravenous administration." Can J Anaesth 42 (1995): 338-40
- Tamari I, Eldar M, Rabinowitz B, Neufeld HN "Medical treatment of cardiovascular disorders during pregnancy." Am Heart J 104 (1982): 1357-63
- Shnider SM, Way EL "Plasma levels of lidocaine (Xylocaine) in mother and newborn following obstetrical conduction anesthesia: clinical applications." Anesthesiology 29 (1968): 951-8
- Kuhnert BR, Philipson EH, Pimental R, et al "Lidocaine disposition in mother, fetus, and neonate after spinal anesthesia." Anesth Analg 65 (1986): 139-44
- Page RL "Treatment of arrhythmias during pregnancy." Am Heart J 130 (1995): 871-6
- Kuhnert BR, Knapp DR, Kuhnert PM, Prochaska AL "Maternal, fetal, and neonatal metabolism of lidocaine." Clin Pharmacol Ther 26 (1979): 213-20
- Kileff M, James FM, Dewan D, Floyd H, DiFazio C "Neonatal neurobehavioral responses after epidural anesthesia for cesarean section with lidocaine and bupivacaine." Anesthesiology 57 Suppl (1982): a403
- Wood M, Wood AJ "Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant." Clin Pharmacol Ther 29 (1981): 522-6
References for breastfeeding information
- Lebedevs TH, Wojnar-Horton RE, Yapp P, Roberts MJ, Dusci LJ, Hackett LP, Ilett K "Excretion of lignocaine and its metabolite monoethylglycinexylidide in breast milk following its use in a dental procedure. A case report." J Clin Periodontol 20 (1993): 606-8
- Zeisler JA, Gaarder TD, De Mesquita SA "Lidocaine excretion in breast milk." Drug Intell Clin Pharm 20 (1986): 691-3
- Roberts RJ, Blumer JL, Gorman RL, et al "American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk." Pediatrics 84 (1989): 924-36
- "Product Information. Xylocaine (lidocaine)." Astra USA, Westborough, MA.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.